Vident Investment Advisory, LLC - CRISPR THERAPEUTICS AG ownership

CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 397 filers reported holding CRISPR THERAPEUTICS AG in Q4 2022. The put-call ratio across all filers is 0.90 and the average weighting 0.2%.

Quarter-by-quarter ownership
Vident Investment Advisory, LLC ownership history of CRISPR THERAPEUTICS AG
ValueSharesWeighting
Q2 2023$490,731
-54.7%
8,746
-63.5%
0.02%
-51.4%
Q1 2023$1,083,395
+24.7%
23,953
+12.1%
0.04%
+6.1%
Q4 2022$868,731
+13.9%
21,371
+40.7%
0.03%
+32.0%
Q3 2022$763,000
-0.8%
15,189
+19.7%
0.02%
+8.7%
Q2 2022$769,000
-27.3%
12,694
-24.7%
0.02%
-17.9%
Q1 2022$1,058,000
-5.3%
16,856
+14.4%
0.03%
-3.4%
Q4 2021$1,117,000
-22.4%
14,734
+14.6%
0.03%
-32.6%
Q3 2021$1,439,000
-37.6%
12,854
-9.7%
0.04%
-38.6%
Q2 2021$2,305,000
+61.8%
14,238
+21.8%
0.07%
+45.8%
Q1 2021$1,425,000
-20.6%
11,694
-0.3%
0.05%
-34.2%
Q4 2020$1,795,000
-2.9%
11,726
-46.9%
0.07%
-20.7%
Q3 2020$1,849,000
+9.8%
22,103
-3.6%
0.09%
+4.5%
Q2 2020$1,684,000
+72.7%
22,922
-0.3%
0.09%
+37.5%
Q1 2020$975,000
-32.1%
22,989
-2.4%
0.06%
-28.1%
Q4 2019$1,435,000
+9.7%
23,556
-26.2%
0.09%
-21.9%
Q3 2019$1,308,000
-15.4%
31,921
-2.8%
0.11%
-8.1%
Q2 2019$1,546,00032,8330.12%
Other shareholders
CRISPR THERAPEUTICS AG shareholders Q4 2022
NameSharesValueWeighting ↓
Versant Venture Management, LLC 498,558$32,581,00055.55%
NEA Management Company, LLC 1,590,002$103,907,0005.19%
ARK Investment Management 8,237,122$538,296,0003.75%
Nikko Asset Management Americas, Inc. 4,262,736$277,078,0003.54%
CLOUGH CAPITAL PARTNERS L P 414,767$27,105,0002.89%
Integral Health Asset Management, LLC 220,000$14,377,0002.79%
PLUSTICK MANAGEMENT LLC 50,000$3,268,0002.48%
HC Advisors, LLC 53,944$3,525,0002.43%
Green Alpha Advisors, LLC 27,466$1,795,0001.52%
EFG Asset Management (North America) Corp. 84,356$5,516,0001.28%
View complete list of CRISPR THERAPEUTICS AG shareholders